Search Results - "Bang, Yung Jue"

HER2-targeted therapies — a role beyond breast cancer by Oh, Do-Youn, Bang, Yung-Jue

“…HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib,…”
Get full text

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer by Shitara, Kohei, Bang, Yung-Jue, Iwasa, Satoru, Sugimoto, Naotoshi, Ryu, Min-Hee, Sakai, Daisuke, Chung, Hyun-Cheol, Kawakami, Hisato, Yabusaki, Hiroshi, Lee, Jeeyun, Saito, Kaku, Kawaguchi, Yoshinori, Kamio, Takahiro, Kojima, Akihito, Sugihara, Masahiro, Yamaguchi, Kensei

“…Approximately 15 to 20% of gastric adenocarcinomas express HER2. Trastuzumab deruxtecan is an antibody-drug conjugate composed of trastuzumab and the…”
Get full text

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study by Marabelle, Aurélien, Fakih, Marwan, Lopez, Juanita, Shah, Manisha, Shapira-Frommer, Ronnie, Nakagawa, Kazuhiko, Chung, Hyun Cheol, Kindler, Hedy L, Lopez-Martin, Jose A, Miller, Wilson H, Italiano, Antoine, Kao, Steven, Piha-Paul, Sarina A, Delord, Jean-Pierre, McWilliams, Robert R, Fabrizio, David A, Aurora-Garg, Deepti, Xu, Lei, Jin, Fan, Norwood, Kevin, Bang, Yung-Jue

“…Tumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of…”
Get full text

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial by Shitara, Kohei, Lordick, Florian, Bang, Yung-Jue, Enzinger, Peter, Ilson, David, Shah, Manish A, Van Cutsem, Eric, Xu, Rui-Hua, Aprile, Giuseppe, Xu, Jianming, Chao, Joseph, Pazo-Cid, Roberto, Kang, Yoon-Koo, Yang, Jianning, Moran, Diarmuid, Bhattacharya, Pranob, Arozullah, Ahsan, Park, Jung Wook, Oh, Mok, Ajani, Jaffer A

“…Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.2), has shown efficacy in patients with CLDN18.2-positive, human epidermal growth…”
Get full text

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial by Bang, Yung-Jue, Xu, Rui-Hua, Chin, Keisho, Lee, Keun-Wook, Park, Se Hoon, Rha, Sun Young, Shen, Lin, Qin, Shukui, Xu, Nong, Im, Seock-Ah, Locker, Gershon, Rowe, Phil, Shi, Xiaojin, Hodgson, Darren, Liu, Yu-Zhen, Boku, Narikazu

“…Olaparib combined with paclitaxel has previously shown a significant improvement in overall survival versus placebo plus paclitaxel as second-line therapy in a…”
Get full text

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer by Bang, Yung-Jue, Cho, Jae Yong, Kim, Yeul Hong, Kim, Jin Won, Di Bartolomeo, Maria, Ajani, Jaffer A, Yamaguchi, Kensei, Balogh, Agnes, Sanchez, Teresa, Moehler, Markus

“…Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity…”
Get full text

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study by Ott, Patrick A, Bang, Yung-Jue, Berton-Rigaud, Dominique, Elez, Elena, Pishvaian, Michael J, Rugo, Hope S, Puzanov, Igor, Mehnert, Janice M, Aung, Kyaw L, Lopez, Juanita, Carrigan, Marion, Saraf, Sanatan, Chen, Mei, Soria, Jean-Charles

“…Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1…”
Get full text

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial by Shah, Manish A., Shitara, Kohei, Ajani, Jaffer A., Bang, Yung-Jue, Enzinger, Peter, Ilson, David, Lordick, Florian, Van Cutsem, Eric, Gallego Plazas, Javier, Huang, Jing, Shen, Lin, Oh, Sang Cheul, Sunpaweravong, Patrapim, Soo Hoo, Hwoei Fen, Turk, Haci Mehmet, Oh, Mok, Park, Jung Wook, Moran, Diarmuid, Bhattacharya, Pranob, Arozullah, Ahsan, Xu, Rui-Hua

“…There is an urgent need for first-line treatment options for patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced…”
Get full text

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial by Muro, Kei, Dr, Chung, Hyun Cheol, Prof, Shankaran, Veena, MD, Geva, Ravit, MD, Catenacci, Daniel, MD, Gupta, Shilpa, MD, Eder, Joseph Paul, MD, Golan, Talia, MD, Le, Dung T, MD, Burtness, Barbara, MD, McRee, Autumn J, MD, Lin, Chia-Chi, MD, Pathiraja, Kumudu, MA, Lunceford, Jared, PhD, Emancipator, Kenneth, MD, Juco, Jonathan, MD, Koshiji, Minori, MD, Bang, Yung-Jue, Prof

“…Summary Background Expression of PD-L1 has been shown to be upregulated in some patients with gastric cancer. As part of the phase 1b KEYNOTE-012 study, we…”
Get full text

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer by Van Cutsem, Eric, Bang, Yung-Jue, Feng-yi, Feng, Xu, Jian M., Lee, Keun-Wook, Jiao, Shun-Chang, Chong, Jorge León, López-Sanchez, Roberto I., Price, Timothy, Gladkov, Oleg, Stoss, Oliver, Hill, Julie, Ng, Vivian, Lehle, Michaela, Thomas, Marlene, Kiermaier, Astrid, Rüschoff, Josef

“…Background In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with…”
Get full text

Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 by Tahara, Makoto, Muro, Kei, Hasegawa, Yasuhisa, Chung, Hyun Cheol, Lin, Chia‐Chi, Keam, Bhumsuk, Takahashi, Kenichi, Cheng, Jonathan D., Bang, Yung‐Jue

“…KEYNOTE‐012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of…”
Get full text

Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial by Fujitani, Kazumasa, MD, Yang, Han-Kwang, Prof, Mizusawa, Junki, MSc, Kim, Young-Woo, MD, Terashima, Masanori, MD, Han, Sang-Uk, MD, Iwasaki, Yoshiaki, MD, Hyung, Woo Jin, MD, Takagane, Akinori, MD, Park, Do Joong, MD, Yoshikawa, Takaki, MD, Hahn, Seokyung, PhD, Nakamura, Kenichi, MD, Park, Cho Hyun, MD, Kurokawa, Yukinori, MD, Bang, Yung-Jue, Prof, Park, Byung Joo, Prof, Sasako, Mitsuru, Prof, Tsujinaka, Toshimasa, Dr

“…Summary Background Chemotherapy is the standard of care for incurable advanced gastric cancer. Whether the addition of gastrectomy to chemotherapy improves…”
Get full text

Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer by Bang, Yung-Jue

“…In the past, patients with advanced or metastatic gastric or gastroesophageal junction cancer have had few treatment options and generally poor survival rates…”
Get full text

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer by Shaw, Alice T, Ou, Sai-Hong I, Bang, Yung-Jue, Camidge, D. Ross, Solomon, Benjamin J, Salgia, Ravi, Riely, Gregory J, Varella-Garcia, Marileila, Shapiro, Geoffrey I, Costa, Daniel B, Doebele, Robert C, Le, Long Phi, Zheng, Zongli, Tan, Weiwei, Stephenson, Patricia, Shreeve, S. Martin, Tye, Lesley M, Christensen, James G, Wilner, Keith D, Clark, Jeffrey W, Iafrate, A. John

“…About 1% of non–small-cell lung cancers have ROS1 rearrangements. This oncogene is inhibited by crizotinib. In a cohort of 50 patients with ROS1 -rearranged…”
Get full text

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial by Bang, Yung-Jue, Prof, Van Cutsem, Eric, Prof, Feyereislova, Andrea, MD, Chung, Hyun C, Prof, Shen, Lin, Prof, Sawaki, Akira, MD, Lordick, Florian, MD, Ohtsu, Atsushi, MD, Omuro, Yasushi, MD, Satoh, Taroh, MD, Aprile, Giuseppe, MD, Kulikov, Evgeny, MD, Hill, Julie, PhD, Lehle, Michaela, PhD, Rüschoff, Josef, Prof, Kang, Yoon-Koo, Prof

“…Summary Background Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in…”
Get full text

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors by Raymond, Eric, Dahan, Laetitia, Raoul, Jean-Luc, Bang, Yung-Jue, Borbath, Ivan, Lombard-Bohas, Catherine, Valle, Juan, Metrakos, Peter, Smith, Denis, Vinik, Aaron, Chen, Jen-Shi, Hörsch, Dieter, Hammel, Pascal, Wiedenmann, Bertram, Van Cutsem, Eric, Patyna, Shem, Lu, Dongrui Ray, Blanckmeister, Carolyn, Chao, Richard, Ruszniewski, Philippe

“…In this trial, daily oral sunitinib was associated with a median progression-free survival of 11.4 months, as compared with 5.5 months for placebo (hazard…”
Get full text

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts by Bang, Yung‐Jue, Su, Wu‐Chou, Schuler, Martin, Nam, Do‐Hyun, Lim, Wan Teck, Bauer, Todd M., Azaro, Analia, Poon, Ronnie Tung Ping, Hong, David, Lin, Chia‐Chi, Akimov, Mikhail, Ghebremariam, Samson, Zhao, Sylvia, Giovannini, Monica, Ma, Brigette

“…Capmatinib is an oral, ATP‐competitive, and highly potent, type 1b MET inhibitor. Herein, we report phase 1 dose‐escalation results for capmatinib in advanced…”
Get full text

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer by Park, Sehhoon, Ock, Chan-Young, Kim, Hyojin, Pereira, Sergio, Park, Seonwook, Ma, Minuk, Choi, Sangjoon, Kim, Seokhwi, Shin, Seunghwan, Aum, Brian Jaehong, Paeng, Kyunghyun, Yoo, Donggeun, Cha, Hongui, Park, Sunyoung, Suh, Koung Jin, Jung, Hyun Ae, Kim, Se Hyun, Kim, Yu Jung, Sun, Jong-Mu, Chung, Jin-Haeng, Ahn, Jin Seok, Ahn, Myung-Ju, Lee, Jong Seok, Park, Keunchil, Song, Sang Yong, Bang, Yung-Jue, Choi, Yoon-La, Mok, Tony S, Lee, Se-Hoon

“…Biomarkers on the basis of tumor-infiltrating lymphocytes (TIL) are potentially valuable in predicting the effectiveness of immune checkpoint inhibitors (ICI)…”
Get full text

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN— A Randomized, Phase III Study by SATOH, Taroh, XU, Rui-Hua, MIWA, Hiroto, QIN, Shu-Kui, CHUNG, Ik-Joo, YEH, Kun-Huei, FENG, Ji-Feng, MUKAIYAMA, Akihira, KOBAYASHI, Mikiro, OHTSU, Atsushi, BANG, Yung-Jue, HYUN CHEOL CHUNG, SUN, Guo-Ping, DOI, Toshihiko, XU, Jian-Ming, TSUJI, Akihito, OMURO, Yasushi, JIN LI, WANG, Jin-Wan

“…In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2…”
Get full text

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial by Noh, Sung Hoon, Prof, Park, Sook Ryun, MD, Yang, Han-Kwang, Prof, Chung, Hyun Cheol, Prof, Chung, Ik-Joo, Prof, Kim, Sang-Woon, Prof, Kim, Hyung-Ho, MD, Choi, Jin-Hyuk, Prof, Kim, Hoon-Kyo, Prof, Yu, Wansik, Prof, Lee, Jong Inn, MD, Shin, Dong Bok, Prof, Ji, Jiafu, Prof, Chen, Jen-Shi, MD, Lim, Yunni, MS, Ha, Stella, MS, Bang, Yung-Jue, Prof

“…Summary Background The CLASSIC trial was done to compare adjuvant capecitabine plus oxaliplatin versus observation after D2 gastrectomy for patients with stage…”
Get full text